ARTICLE | Company News
Almirall, Kyorin, AstraZeneca deal
February 15, 2016 8:00 AM UTC
AstraZeneca and Kyorin terminated part of a 2011 deal granting Kyorin rights to develop aclidinium bromide in Japan as monotherapy or in combination with formoterol fumarate. Rights to the combination product, KRP-AB1102F, will revert to AZ, which purchased Almirall’s respiratory disease business in 2014. ...